dc.relation.references | Simonneau, G., Montani, D., Celermajer, D. S., et al. (2019). Haemodynamic definitions and updated clinical classification of pulmonary hypertension. European Respiratory Journal, 53(1), 1801913. https://doi.org/10.1183/13993003.01913-2018 - 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. 2. Marc Humbert, Gabor Kovacs, Marius M. Hoeper, Roberto Badagliacca, Rolf M.F. Berger, Margarita Brida, Jørn Carlsen, Andrew J.S. Coats, Pilar Escribano-Subias, Pisana Ferrari, Diogenes S. Ferreira, Hossein Ardeschir Ghofrani, George Giannakoulas, David G. Kiely, Eckhard Mayer, Gergely Meszaros, Blin Nagavci, Karen M. Olsson, Joanna Pepke-Zaba, Jennifer K. Quint, Göran Rådegran, Gerald Simonneau, Olivier Sitbon, Thomy Tonia, MarkToshner, JeanLuc Vachiery, Anton Vonk Noordegraaf, Marion Delcroix, Stephan Rosenkranz, the ESC/ERS Scientific Document Group. European Respiratory Journal Jan 2023, 61 (1) 2200879; DOI: 10.1183/13993003.00879-2022 3. Ramos RP, et al. "Benefícios e limitações do tratamento atual da hipertensão arterial pulmonar". Rev Soc Cardiol Estado de São Paulo, 2011. 4. Souza R, et al. "Análise contemporânea da história natural da hipertensão arterial pulmonar". Rev Soc Cardiol Estado de São Paulo, 2011. 5. The importance of the World Symposium on Pulmonary Hypertension / A importância do Simpósio Mundial de Hipertensão Pulmonar Jardim, Carlos; Waetge, Daniel. J. bras. pneumol ; 44(3): 173-174, May-June 2018.http://dx.doi.org/10.1590/S1806-37562018000030001 6. Fernandes CJ, Calderaro D, Assad APL, Salibe-Filho W, KatoMorinaga LT, Hoette S, Piloto B, Castro MA, Lisboa RP, Silva TAFD, Martins MA, Alves-Jr JL, Jardim C, Terra-Filho M, Souza R. Update on the Treatment of Pulmonary Arterial Hypertension. Arq Bras Cardiol. 2021 Oct;117(4):750-764. English, Portuguese. doi: 10.36660/abc.20200702. PMID: 34709302; PMCID: PMC8528352. 7. Hoeper MM, Pausch C, Olsson KM, Huscher D, Pittrow D, Grünig E, Staehler G, Vizza CD, Gall H, Distler O, Opitz C, Gibbs JSR, Delcroix M, Ghofrani HA, Park DH, Ewert R, Kaemmerer H, Kabitz HJ, Skowasch D, Behr J, Milger K, Halank M, Wilkens H, Seyfarth HJ, Held M, Dumitrescu D, Tsangaris I, Vonk-Noordegraaf A, Ulrich S, Klose H, Claussen M, Lange TJ, Rosenkranz S. COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. Eur Respir J. 2022 Jul 7;60(1):2102311. doi: 10.1183/13993003.02311-2021. PMID: 34737226; PMCID: PMC9260123. 8. McLaughlin, V. V., Archer, S. L., Badesch, D. B., et al. (2019). ACC/AHA 2018 multisociety guideline on the diagnosis, evaluation, 27 and treatment of pulmonary hypertension. Journal of the American College of Cardiology, 73(24), e165-e191. https://doi.org/10.1016/j.jacc.2018.10.107 9. Chin KM, Channick RN, Rubin LJ. Is methamphetamine use associated with idiopathic pulmonary arterial hypertension? Chest. 2006 Dec;130(6):1657-63. doi: 10.1378/chest.130.6.1657. PMID: 17166979. 10. Lopes AA, Barst RJ, Haworth SG, Rabinovitch M, Al Dabbagh M, Del Cerro MJ, Ivy D, Kashour T, Kumar K, Harikrishnan S, D'Alto M, Thomaz AM, Zorzanelli L, Aiello VD, Mocumbi AO, Santana MV, Galal AN, Banjar H, Tamimi O, Heath A, Flores PC, Diaz G, Sandoval J, Kothari S, Moledina S, Gonçalves RC, Barreto AC, Binotto MA, Maia M, Al Habshan F, Adatia I. Repair of congenital heart disease with associated pulmonary hypertension in children: what are the minimal investigative procedures? Consensus statement from the Congenital Heart Disease and Pediatric Task Forces, Pulmonary Vascular Research Institute (PVRI). Pulm Circ. 2014 Jun;4(2):330-41. doi: 10.1086/675995. Erratum in: Pulm Circ. 2014 Sep;4(3):531. PMID: 25006452; PMCID: PMC4070778. 11. Humbert M. Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology. Eur Respir Rev. 2010 Mar;19(115):59-63. doi: 10.1183/09059180.00007309. PMID: 20956167; PMCID: PMC9491634. 12. Barnes H, Yeoh HL, Fothergill T, Burns A, Humbert M, Williams T. Prostacyclin for pulmonary arterial hypertension. Cochrane Database Syst Rev. 2019 May 1;5(5):CD012785. doi: 10.1002/14651858.CD012785.pub2. PMID: 31042010; PMCID: PMC6492481. 13. Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, Preiss R, Rubin LJ, Di Scala L, Tapson V, Adzerikho I, Liu J, Moiseeva O, Zeng X, Simonneau G, McLaughlin VV; GRIPHON Investigators. Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2015 Dec 24;373(26):2522-33. doi: 10.1056/NEJMoa1503184. PMID: 26699168. 14. Galiè N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Gerber MJ, Dufton C, Wiens BL, Rubin LJ; Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, doubleblind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008 Jun 10;117(23):3010-9. doi: 10.1161/CIRCULATIONAHA.107.742510. Epub 2008 May 27. PMID: 18506008. 15. Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G; Sildenafil Use in Pulmonary Arterial Hypertension 28 (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005 Nov 17;353(20):2148-57. doi: 10.1056/NEJMoa050010. Erratum in: N Engl J Med. 2006 Jun 1;354(22):2400-1. PMID: 16291984. 16. Lajoie AC, Lauzière G, Lega JC, Lacasse Y, Martin S, Simard S, Bonnet S, Provencher S. Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis. Lancet Respir Med. 2016 Apr;4(4):291-305. doi: 10.1016/S2213-2600(16)00027-8. Epub 2016 Feb 27. Erratum in: Lancet Respir Med. 2016 Jun;4(6):e34. PMID: 26935844. 17. Rosenkranz S, Gibbs JS, Wachter R, De Marco T, Vonk-Noordegraaf A, Vachiéry JL. Left ventricular heart failure and pulmonary hypertension. Eur Heart J. 2016 Mar 21;37(12):942-54. doi: 10.1093/eurheartj/ehv512. Epub 2015 Oct 27. PMID: 26508169; PMCID: PMC4800173. 18. Caravita S, Dewachter C, Soranna D, D'Araujo SC, Khaldi A, Zambon A, Parati G, Bondue A, Vachiéry JL. Haemodynamics to predict outcome in pulmonary hypertension due to left heart disease: a metaanalysis. Eur Respir J. 2018 Apr 4;51(4):1702427. doi: 10.1183/13993003.02427-2017. PMID: 29439019. 19. Nathan SD, Barbera JA, Gaine SP, Harari S, Martinez FJ, Olschewski H, Olsson KM, Peacock AJ, Pepke-Zaba J, Provencher S, Weissmann N, Seeger W. Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J. 2019 Jan 24;53(1):1801914. doi: 10.1183/13993003.01914-2018. PMID: 30545980; PMCID: PMC6351338. 20. Blanco I, Santos S, Gea J, Güell R, Torres F, Gimeno-Santos E, Rodriguez DA, Vilaró J, Gómez B, Roca J, Barberà JA. Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial. Eur Respir J. 2013 Oct;42(4):982-92. doi: 10.1183/09031936.00176312. Epub 2013 Feb 21. PMID: 23429918. 21. Delcroix M, Torbicki A, Gopalan D, Sitbon O, Klok FA, Lang I, Jenkins D, Kim NH, Humbert M, Jais X, Vonk Noordegraaf A, Pepke-Zaba J, Brénot P, Dorfmuller P, Fadel E, Ghofrani HA, Hoeper MM, Jansa P, Madani M, Matsubara H, Ogo T, Grünig E, D'Armini A, Galie N, Meyer B, Corkery P, Meszaros G, Mayer E, Simonneau G. ERS statement on chronic thromboembolic pulmonary hypertension. Eur Respir J. 2021 Jun 17;57(6):2002828. doi: 10.1183/13993003.028282020. PMID: 33334946. 22. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, Huisman MV, Humbert M, Jennings CS, Jiménez D, Kucher N, Lang IM, Lankeit M, Lorusso R, Mazzolai L, Meneveau N, Ní Áinle F, Prandoni P, Pruszczyk P, Righini M, Torbicki A, Van Belle E, Zamorano JL; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020 Jan 21;41(4):543-603. doi: 10.1093/eurheartj/ehz405. PMID: 31504429. | pt_BR |